Citations

Clear

431 citation(s) found for "Schmidt, B".

Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis
Karau, Melissa J., Schmidt-Malan, Suzannah M., Cunningham, Scott A., Mandrekar, Jayawant N., Pritt, Bobbi S. , Keepers, Tiffany R., Serio, Alisa W., Chitra, Surya, Patel, Robin , Patel, Robin , Pritt, Bobbi S , Karau, Melissa J., Schmidt-Malan, Suzannah M., Cunningham, Scott A., Mandrekar, Jayawant N., Keepers, Tiffany R., Serio, Alisa W., Chitra, Surya

Mayo Clinic

Antimicrobial Agents and Chemotherapy | November 1, 2021 | Volume: 66 | Issue: 1 | Pages: No page available

10.1128/aac.01703-21 | PMID 34723626 Get It

Omadacycline, vancomycin, and rifampin, as well as rifampin combination therapies, were evaluated in an experimental rat model of methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis. All treatment groups had less MRSA recovered than saline-treated animals.
Acute kidney injury in patients treated with immune checkpoint inhibitors
Short, Samuel , Sise, Meghan E. , Prosek, Jason, Madhavan, Sethu M. , Soler, María José , Ostermann, Marlies , Abudayyeh, Ala , Anand, Shuchi , Motwani, Shveta S. , Murakami, Naoka , Wanchoo, Rimda, Ortiz-Melo, David I. , Rashidi, Arash , Aggarwal, Vikram , Malik, Abhinav , Loew, Sebastian, Carlos, Christopher A., Chang, Wei‐Ting , Beckerman, Pazit , Mithani, Zain, Renaghan, Amanda DeMauro , Seigneux, Sophie de , Campedel, Luca , Shin, Daniel Sanghoon , Rangarajan, Sunil , Deshpande, Priya , Coppock, Gaia, Eijgelsheim, Mark, Lee, Meghan , Husain, Marium , García-Carro, Clara , Bermejo, Sheila , Lumlertgul, Nuttha , Seylanova, Nina , Flanders, Lucy , Isik, Busra , Mamlouk, Omar , García, Pablo , Kaghazchi, Aydin , Khanin, Yuriy, Kansal, Sheru, Wauters, Els , Chandra, Sunandana , Hsu, Raymond K. , Tio, Maria Clarissa , Mothi, Suraj Sarvode, Singh, Harkarandeep , Reynolds, Kerry L. , Cortazar, Frank B. , Leaf, David E. , Salem, Joe‐Elie , Gupta, Shruti , Kitchlu, Abhijat , Lee, Meghan D , Mamlouk, Omar , Lin, Jamie S , Leaf, David E , Murakami, Naoka , Soler, Maria Jose , Salem, Joe-Elie , Hsu, Raymond K , Ostermann, Marlies , Koessler, Thibaud , Gupta, Shruti , Herrmann, Sandra M. , Glezerman, Ilya G , Sprangers, Ben , Malik, A Bilal, Shah, Chintan V , Kitchlu, Abhijat , Seethapathy, Harish Shanthanu , Strohbehn, Ian A. , Owen, Dwight H , Schmidt-Ott, Kai Martin , Schrag, Deborah , Jhaveri, Kenar D.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 10, 2021 | Volume: 9 | Issue: 10 | Pages: e003467

10.1136/jitc-2021-003467 | PMID 34625513 Get It

Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. Methods We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI. Results ICPi-AKI occurred at a median of 16 weeks (IQR 8–32) following ICPi initiation. Lower baseline estimated glomerular filtration rate, proton pump inhibitor (PPI) use, and extrarenal immune-related adverse events (irAEs) were each associated with a higher risk of ICPi-AKI. Acute tubulointerstitial nephritis was the most common lesion on kidney biopsy (125/151 biopsied patients [82.7%]). Renal recovery occurred in 276 patients (64.3%) at a median of 7 weeks (IQR 3–10) following ICPi-AKI. Treatment with corticosteroids within 14 days following ICPi-AKI diagnosis was associated with higher odds of renal recovery (adjusted OR 2.64; 95% CI 1.58 to 4.41). Among patients treated with corticosteroids, early initiation of corticosteroids (within 3 days of ICPi-AKI) was associated with a higher odds of renal recovery compared with later initiation (more than 3 days following ICPi-AKI) (adjusted OR 2.09; 95% CI 1.16 to 3.79). Of 121 patients rechallenged, 20 (16.5%) developed recurrent ICPi-AKI. There was no difference in survival among patients rechallenged versus those not rechallenged following ICPi-AKI. Conclusions Patients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery.
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
Slingluff, Craig L. , Lewis, Karl D. , Andtbacka, Robert Hans Ingemar, Hyngstrom, John , Milhem, Mohammed , Bowles, Tawnya L. , Hamid, Omid , Hernandez‐Aya, Leonel F. , Claveau, Joël, Jang, Sekwon, Philips, Prejesh, Holtan, Shernan G. , Shaheen, Montaser , Curti, Brendan D. , Schmidt, William, Butler, Marcus O. , Paramo, Juan, Lutzky, Jose , Padmanabhan, Arvinda, Thomas, Sajeve , Milton, Daniel T., Pecora, Andrew L. , Sato, Takami , Hsueh, Eddy C. , Badarinath, Suprith, Keech, John A., Kalmadi, Sujith, Kumar, Pallavi , Weber, Robert, Levine, Edward A. , Berger, Adam C. , Bar, Anna, Travers, Jeffrey B. , Mihalcioiu, Catalin , Gastman, Brian , Beitsch, Peter D. , Rapisuwon, Suthee , McCarron, Edward C. , Gupta, Vinay , Behl, Deepti , Blumenstein, Brent A. , Peterkin, Joanna, Curti, Brendan , Lutzky, Jose , Rapisuwon, Suthee , Milhem, Mohammed M , Butler, Marcus O , Levine, Edward A , Holtan, Shernan , Markovic, Svetomir N. , Paramo, Juan, Milton, Daniel, Beck, J. Thaddeus , Glaspy, John A.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 1, 2021 | Volume: 9 | Issue: 10 | Pages: e003272

10.1136/jitc-2021-003272 | PMID 34599031 Get It

Background Most patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plus alum. To assess the efficacy of seviprotimut-L, the Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) was initiated as a three-part multicenter, double-blind, placebo-controlled phase III trial. Results from part B1 are reported here. Methods Patients with AJCC V.7 stage IIB-III cutaneous melanoma after resection were randomized 2:1, with stage stratification (IIB/C, IIIA, IIIB/C), to seviprotimut-L 40 mcg or placebo. Recurrence-free survival (RFS) was the primary endpoint. For an hypothesized HR of 0.625, one-sided alpha of 0.10, and power 80%, target enrollment was 325 patients. Results For randomized patients (n=347), arms were well-balanced, and treatment-emergent adverse events were similar for seviprotimut-L and placebo. For the primary intent-to-treat endpoint of RFS, the estimated HR was 0.881 (95% CI: 0.629 to 1.233), with stratified logrank p=0.46. However, estimated HRs were not uniform over the stage randomized strata, with HRs (95% CIs) for stages IIB/IIC, IIIA, IIIB/IIIC of 0.67 (95% CI: 0.37 to 1.19), 0.72 (95% CI: 0.35 to 1.50), and 1.19 (95% CI: 0.72 to 1.97), respectively. In the stage IIB/IIC stratum, the effect on RFS was greatest for patients <60 years old (HR=0.324 (95% CI: 0.121 to 0.864)) and those with ulcerated primary melanomas (HR=0.493 (95% CI: 0.255 to 0.952)). Conclusions Seviprotimut-L is very well tolerated. Exploratory efficacy model estimation supports further study in stage IIB/IIC patients, especially younger patients and those with ulcerated melanomas. Trial registration number NCT01546571.
Surgical treatment of brainstem cavernous malformations: an international Delphi consensus
Dammann, Philipp , Abla, Adib A. , Salman, Rustam Al‐Shahi , Cenzato, Marco , Connolly, E. Sander , Cornelius, Jan F. , Hauck, Erik F. , Hernesniemi, Juha , Kivelev, Juri , MacDonald, Ryan , Ogilvy, Christopher S. , Steiger, Hans‐Jakob , Steinberg, Gary K. , Rauschenbach, Laurèl , Schmidt, Börge , Spetzler, Robert F., Schaller, Karl , Lawton, Michael T. , Abla, Adib , Ogilvy, Christopher S , Al-Shahi Salman, Rustam , Steinberg, Gary K , Rauschenbach, Laurèl , Andrade-Barazarte, Hugo , Beneš, Vladimír , Couldwell, William T. , Sola, Rafael García de , Gomez‐Paz, Santiago , Lanzino, Giuseppe , Macdonald, R. Loch, Morcos, Jacques J. , Santos, Alejandro N. , Oppong, Marvin Darkwah , Sure, Ulrich

Mayo Clinic

Journal of Neurosurgery | October 1, 2021 | Volume: 136 | Issue: 5 | Pages: 1220-1230

10.3171/2021.3.jns2156 | PMID 34598135 Get It

OBJECTIVE Indication for surgery in brainstem cavernous malformations (BSCMs) is based on many case series, few comparative studies, and no randomized controlled trials. The objective of this study was to seek consensus about surgical management aspects of BSCM. METHODS A total of 29 experts were invited to participate in a multistep Delphi consensus process on the surgical treatment of BSCM. RESULTS Twenty-two (76%) of 29 experts participated in the consensus. Qualitative analysis (content analysis) of an initial open-ended question survey resulted in 99 statements regarding surgical treatment of BSCM. By using a multistep survey with 100% participation in each round, consensus was reached on 52 (53%) of 99 statements. These were grouped into 4 categories: 1) definitions and reporting standards (7/14, 50%); 2) general and patient-related aspects (11/16, 69%); 3) anatomical-, timing of surgery–, and BSCM-related aspects (22/37, 59%); and 4) clinical situation–based decision-making (12/32, 38%). Among other things, a consensus was reached for surgical timing, handling of associated developmental venous anomalies, handling of postoperative BSCM remnants, assessment of specific anatomical BSCM localizations, and treatment decisions in typical clinical BSCM scenarios. CONCLUSIONS A summary of typical clinical scenarios and a catalog of various BSCM- and patient-related aspects that influence the surgical treatment decision have been defined, rated, and interpreted.
Radiomics Derived Brain Age Predicts Functional Outcome After Acute Ischemic Stroke
Bretzner, Martin , Bonkhoff, Anna K. , Schirmer, Markus D. , Hong, Sung‐Min , Donahue, Kathleen, Etherton, Mark R. , Rist, Pamela M. , Nardin, Marco, Regenhardt, Robert W. , Leclerc, X. , Gautherot, Morgan , Wang, Clinton, Benavente, Oscar, Donatti, Amanda , Heitsch, Laura , Jiménez-Conde, Jordi , Kittner, Steven J. , McArdle, Patrick, Rolfs, Arndt , Schmidt, Reinhold, Sharma, Pankaj , Słowik, Agnieszka , Sousa, Alessandro Viana Oliveira e, Strbian, Daniel , Wassélius, Johan , Woo, Daniel , Worrall, Bradford B. , Maguire, Jane , Golland, Polina , Kuchcinski, Grégory , Rost, Natalia S. , Bretzner, Martin , Strbian, Daniel , Regenhardt, Robert W , Dalca, Adrian Vasile , Giese, Anne‐Katrin , Lopes, Renaud , Cole, John W. , Griessenauer, Christoph J. , Holmegaard, Lukas , Jood, Katarina , Lemmens, Robin , Levi, Christopher , McDonough, Caitrin W. , Meschia, James F. , Phuah, Chia‐Ling , Ropele, Stefan , Rosand, Jonathan M. , Roquer, Jaume , Rundek, Tatjana , Sacco, Ralph L. , Sousa, Alessandro Augusto Viana Oliveira e, Stanne, Tara M. , Tatlisumak, Turgut , Thijs, Vincent , Vagal, Achala , Wu, Ona , Zand, Ramin , Lindgren, Arne G. , Jern, Christina

Mayo Clinic

No container title available | September 24, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-923769/v1 Get It

Abstract While chronological age is one of the most influential determinants of post-stroke outcomes, little is known of the impact of neuroimaging-derived biological brain age. We here first examine whether radiomics analysis of the texture of brain T2-FLAIR MRI images can be used to predict brain age in stroke patients. We then assess the clinical determinants of accelerated brain aging and, finally, its impact on post-stroke functional outcomes. Leveraging a multisite cohort of 4,163 ischemic stroke patients, we show that older-appearing patients have more hypertension, diabetes mellitus, prior strokes, and smoking history and are more likely to develop worse post-stroke outcomes than their younger-appearing counterparts. Our results strengthen the importance of preventive medicine for maintaining brain health in stroke patients as they age and suggest a novel methodology to capture previously undescribed prognostic information available on commonly acquired MRI sequences during routine stroke care.
Ketamine infusion as a sedative-analgesic in severe ARDS (KISS)
Pata, Ramakanth , Sandeep, Pagali, Aung, Htun Min , Patel, Meet J, Dolkar, Tsering, Nway, Nway , Kosuru, Bhanu Prasad , Ahmady, Abolfazl , Kiani, Roudabeh, Swaroop, Ramaiah, Schmidt, Frances, Enriquez, Danilo, Patel, Meet J

Mayo Clinic

Journal of Community Hospital Internal Medicine Perspectives | September 20, 2021 | Volume: 11 | Issue: 5 | Pages: 619-623

10.1080/20009666.2021.1948669 | PMID 34567451 Get It

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
Shah, Pankil , Rubinstein, Samuel M. , Joyner, Michael J. , Choueiri, Toni K. , Flora, Daniel , Gulati, Anthony P., Koshkin, Vadim S. , Papadopoulos, Esperanza B. , Robilotti, Elizabeth , Su, Christopher , Wulff‐Burchfield, Elizabeth , Xie, Zhuoer , Yu, Peter Paul , Mishra, Sanjay , Senefeld, Jonathon W. , Shah, Dimpy P. , Verma, Amit , Gartrell, Benjamin A. , Ohri, Nitin , Butt, Omar H. , Campian, Jian , Fiala, Mark A. , Monahan, Ryan, Bohachek, Pamela, Mundt, Daniel , Streckfuss, Mitrianna, Tadesse, Eyob, Lammers, Philip E. , Revankar, Sanjay G. , Khan, Hina, Prete, Salvatore A. Del , Angevine, Anne H., Bär, Michael , Lo, KM Steve, Stratton, Jamie , Weinstein, Paul L., García, Jorge A. , Nakayama, John , Gupta, Shilpa , Ahluwalia, Manmeet S. , Dawsey, Scott J. , Nizam, Amanda , Lemmon, Christopher A. , Hoppenot, Claire , Bakouny, Ziad , Bouchard, Gabrielle, Busser, Fiona, Conners, Jean M, Curran, Catherine , Demetri, George D., Kelleher, Kaitlin M. , Shaw, Grace, Nuzzo, Pier Vitale , Zon, Rebecca L. , Zhang, Tian , Grivas, Petros , Lynch, Ryan C. , Schweizer, Michael T. , Tachiki, Lisa ML, Vinayak, Shaveta , Wagner, Michael J. , Yeh, Albert C. , Goyal, Sharad , Clément, Jessica , Daher, Ahmad , Dailey, Mark E., Hsu, Emily , Menendez, Alvaro G. , Rathmann, Joerg, Serrano, Oscar K. , Jayaraj, Asha, Accordino, Melissa , Mushtaq, Sarah, Bernicker, Eric , Deeken, John F. , Shafer, Danielle , Lewis, Mark A. , Rhodes, Terence D., Gill, David , Low, Clarke A., Nagle, Sarah , Hayes‐Lattin, Brandon , Nemecek, Eneida R. , Zaren, Howard A. , Smith, Stephanie J., Akhtari, Mojtaba, Lau, Eric , Reeves, Mark E. , Elms, Destry, Altman, Jessica K. , Gurley, Michael, Mulcahy, Mary F. , Kulkarni, Amit , Shah, Surbhi, Rosovsky, Rachel , Reynolds, Kerry L. , Bardia, Aditya , Gainor, Justin F. , Zubiri, Leyre , Bonnen, Mark , Mahadevan, Daruka , Salazar, Mary, Belenkaya, Rimma , Riely, Gregory J. , Faller, Bryan A. , McKay, Rana R. , Ajmera, Archana , Cabal, Angelo , Shaya, Justin , Weissmann, Lisa B., Jani, Chinmay , Chen, James L. , Jhawar, Sachin R, Lustberg, Maryam B. , Pillainayagam, Clement, Wall, Sarah , Williams, Nicole , Karivedu, Vidhya , Addison, Daniel , Menon, Harry, Rovito, Marc A., Elshoury, Amro, Shah, Mansi , Mahmood, Sana , Mico, Vasil, Rivera, Andrea Verghese, Miller, Chaim , Cabebe, Elwyn C., Glover, Michael , Jha, Alokkumar , Schapira, Lidia , Shah, Sumit , Subbiah, Suki , Logan, Barbara, Lopes, Gilberto , Russell, Karen , Stith, Brittany, Smits, Melissa, Edwin, Natasha, Chism, David D. , Owenby, Susie, Doroshow, Deborah B. , Galsky, Matthew D. , Zhu, Huili , Fu, Julie , Patel, Kanishka G. , Riess, Jonathan W. , Kwon, Daniel H. , Islam, Jessica Y. , Ahmad, Syed A. , Grover, Punita , Kharofa, Jordan , Marcum, Michelle, Park, Cathleen, Geiger, Christopher L., Bishnoi, Rohit , Feldman, Lawrence , Hoskins, Kent , Gantt, Gerald, Khan, Mahir, Nguyen, Ryan H, Schwartz, Candice, Venepalli, Neeta K. , Kasi, Anup , Fecher, Leslie A. , Mavromatis, Blanche H., Bijjula, Ragneel R., Cheng, Alex , French, Benjamin , Gillaspie, Erin A. , Hennessy, Cassandra , Johnson, Douglas B. , Reid, Sonya , Slosky, David, Solórzano, Carmen C. , Vega-Luna, Karen, Enriquez, Kyle T. , Sun, Tianyi , Carducci, Theresa M., Puc, Matthew , Loon, Susan Van, Goldsmith, Karen J., Rice, Robert, Cabalona, Wilhelmina D., Pilar, Christine, McCollough, Briana Barrow, Peddi, Prakash , Rosen, L, Bilen, Mehmet Asım , Ravindranathan, Deepak , LoRusso, Patricia , Masters, Tyler, Choueiri, Toni K , Bakouny, Ziad , Mishra, Sanjay , Yeh, Albert C , Xie, Zhuoer , Zubiri, Leyre , Su, Christopher , Fiala, Mark A , Joyner, Michael J , Senefeld, Jonathon W , Ahluwalia, Manmeet S , Lustberg, Maryam , Thompson, Michael A. , Henderson, Jeffrey P. , Griffiths, Elizabeth A. , Hwang, Clara , Warner, Jeremy L. , Halmos, Balázs , Goel, Sanjay , Sica, Roberto Alejandro , Thakkar, Astha , Stockerl‐Goldstein, Keith , Zhou, Alice Y. , Tadesse, Eyob, Panagiotou, Orestis A. , Egan, Pamela , Farmakiotis, Dimitrios , Olszewski, Adam J. , Loaiza‐Bonilla, Arturo , Bar, Michael H, Lo, K. M. Steve, Caimi, Paolo F. , Barnholtz‐Sloan, Jill S. , Pennell, Nathan A , Li, Ang , Giordano, Antonio , Nohria, Anju , Schmidt, Andrew , Van Allen, Eliezer M , Xu, Wenxin Vincent , Halabi, Susan , Lyman, Gary H , Graber, Jerome J. , Khaki, Ali Raza , Loggers, Elizabeth T , Nakasone, Elizabeth S. , Tachiki, Lisa M, Gatson, Na Tosha , Huynh‐Le, Minh‐Phuong , Rosenstein, Lori J. , Elias, Rawad , Gadgeel, Shirish M. , Hawley, Jessica E. , Hershman, Dawn L. , Bhutani, Divaya , Schwartz, Gary K. , Reuben, Daniel Y. , McWeeney, Shannon K. , Nagaraj, Gayathri , Berg, Stephanie , Morgans, Alicia K. , Wehbe, Firas , Durbin, Eric B. , Nelson, Heather H. , Boland, Genevieve M. , Hálfdánarson, Þorvarður R. , Bekaii‐Saab, Tanios , Desai, Aakash , Mesa, Ruben A. , Ramirez, Amelie G , Philip, John , Gatti-Mays, Margaret Elena , Jhawar, Sachin R, Palmer, Joshua D. , Stover, Daniel G. , Joshi, Monika , Jabbour, Salma K , Bashir, Babar , McNair, Christopher M. , Wu, Julie , Kloecker, Goetz Hans , Fazio, Alyson, Kumar, Vaibhav , Wood, William A. , Gulati, Shuchi , Wise-Draper, Trisha Michel , Bowles, Daniel W. , Markham, Merry Jennifer , Shah, Chintan , Acoba, Jared David , Rho, Young Soo, Nguyen, Ryan H, Pasquinelli, Mary M. , Vikas, Praveen , Friese, Christopher R. , Zaman, Qamar U, Davis, Elizabeth J. , Hausrath, Daniel J. , Hsu, Chih–Yuan , Li, Xuanyi , Rini, Brian I. , Shyr, Yu , Tucker, Matthew D. , Wang, Lucy Lu , Hafez, Navid , Herbst, Roy S. , Stratton, Catherine

Mayo Clinic

JAMA Oncology | August 19, 2021 | Volume: 7 | Issue: 8 | Pages: 1167

10.1001/jamaoncol.2021.1799 | PMID 34137799 Get It

Polymeric Nanoparticles Active against Dual-Species Bacterial Biofilms
Makabenta, Jessa Marie , Park, Jungmi , Li, Cheng‐Hsuan , Chattopadhyay, Aritra Nath , Nabawy, Ahmed , Landis, Ryan F., Schmidt-Malan, Suzannah M., Patel, Robin , Rotello, Vincent M. , Makabenta, Jessa Marie V , Schmidt-Malan, Suzannah, Rotello, Vincent M , Patel, Robin , Gupta, Akash

Mayo Clinic

Molecules | August 16, 2021 | Volume: 26 | Issue: 16 | Pages: 4958

10.3390/molecules26164958 | PMID 34443542 Get It

Biofilm infections are a global public health threat, necessitating new treatment strategies. Biofilm formation also contributes to the development and spread of multidrug-resistant (MDR) bacterial strains. Biofilm-associated chronic infections typically involve colonization by more than one bacterial species. The co-existence of multiple species of bacteria in biofilms exacerbates therapeutic challenges and can render traditional antibiotics ineffective. Polymeric nanoparticles offer alternative antimicrobial approaches to antibiotics, owing to their tunable physico-chemical properties. Here, we report the efficacy of poly(oxanorborneneimide) (PONI)-based antimicrobial polymeric nanoparticles (PNPs) against multi-species bacterial biofilms. PNPs showed good dual-species biofilm penetration profiles as confirmed by confocal laser scanning microscopy. Broad-spectrum antimicrobial activity was observed, with reduction in both bacterial viability and overall biofilm mass. Further, PNPs displayed minimal fibroblast toxicity and high antimicrobial activity in an in vitro co-culture model comprising fibroblast cells and dual-species biofilms of Escherichia coli and Pseudomonas aeruginosa. This study highlights a potential clinical application of the presented polymeric platform.
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
Drayman, Nir , DeMarco, Jennifer K. , Jones, Krysten A. , Azizi, Saara‐Anne , Froggatt, Heather M. , Tan, Kemin , Maltseva, N. , Chen, Siquan, Nicolaescu, Vlad , Dvorkin, Steve, Furlong, Kevin, Firpo, Mason R. , Mastrodomenico, Vincent , Bruce, Emily A. , Schmidt, Madaline M. , Jedrzejczak, R. , Schuster, Brooke , Nair, Vishnu , Han, Kyu‐Yeon , O’Brien, Amornrat , Τοματσίδου, Αναστασία, Vignuzzi, Marco , Botten, Jason , Brooke, Christopher B. , Lee, Hyun , Severson, William E., Palmer, Kenneth E. , Dickinson, Bryan C. , Joachimiak, A. , Randall, Glenn , Tay, Savaş , Maltseva, Natalia Ivanovna , Kathayat, Rahul S , Bruce, Emily A , Schmidt, Madaline M , Jedrzejczak, Robert , Muñoz-Alía, Miguel Á , Schuster, Brooke , Nair, Vishnu , Han, Kyu-Yeon , Meyer, Bjoern , Vignuzzi, Marco , Botten, Jason W , Brooke, Christopher B , Lee, Hyun , Baker, Susan C , Mounce, Bryan C , Heaton, Nicholas S , Dickinson, Bryan C , Joachimiak, Andrzej , Randall, Glenn , Tay, Savaş , Furlong, Kevin, Muñoz-Alía, Miguel Ángel , Missiakas, Dominique M.

Mayo Clinic

Science | July 20, 2021 | Volume: 373 | Issue: 6557 | Pages: 931-936

10.1126/science.abg5827 | PMID 34285133 Get It

Targeting the main protease of SARS-CoV-2 Inside host cells, the RNA genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is translated into two polyproteins that are cleaved to give the individual viral proteins. The main viral protease, known as Mpro or 3CLpro, plays a key role in these cleavages, making it an important drug target. Drayman et al . identified eight drugs that target 3CLpro from a library of 1900 clinically safe drugs. Because of the challenge of working with SARS-CoV-2, they started by screening for drugs that inhibit the replication of a human coronavirus that causes the common cold. They then evaluated the top hits for inhibiting SARS-CoV-2 replication and for inhibiting 3CLpro. Masitinib, a broad antiviral, inhibited the main proteases of coronaviruses and picornaviruses and was effective in reducing SARS-CoV-2 replication in mice. —VV
Full field-of-view, high-resolution, photon-counting detector CT: technical assessment and initial patient experience
Rajendran, Kishore , Petersilka, Martin, Henning, André , Shanblatt, Elisabeth R. , Marsh, Jeffrey F., Thorne, Jamison E. , Schmidt, Bernhard , Flohr, Thomas , Marsh, Jeffrey, Thorne, Jamison, Fletcher, Joel, McCollough, Cynthia, Rajendran, Kishore , Fletcher, Joel G. , McCollough, Cynthia H. , Leng, Shuai

Mayo Clinic

Physics in Medicine & Biology | July 16, 2021 | Volume: 66 | Issue: 20 | Pages: 205019

10.1088/1361-6560/ac155e | PMID 34271558 Get It

Abstract We report a comprehensive evaluation of a full field-of-view (FOV) photon-counting detector (PCD) computed tomography (CT) system using phantoms, and qualitatively assess image quality in patient examples. A whole-body PCD-CT system with 50 cm FOV, 5.76 cm z-detector coverage and two acquisition modes (standard: 144 × 0.4 mm collimation and ultra-high resolution (UHR): 120 × 0.2 mm collimation) was used in this study. Phantoms were scanned to assess image uniformity, CT number accuracy, noise power spectrum, spatial resolution, material decomposition and virtual monoenergetic imaging (VMI) performance. Four patients were scanned on the PCD-CT system with matched or lower radiation dose than their prior clinical CT scans performed using energy-integrating detector (EID) CT, and the potential clinical impact of PCD-CT was qualitatively evaluated. Phantom results showed water CT numbers within ±5 HU, and image uniformity measured between peripheral and central regions-of-interests to be within ±5 HU. For the UHR mode using a dedicated sharp kernel, the cut-off spatial frequency was 40 line-pairs cm −1 , which corresponds to a 125 μ m limiting in-plane spatial resolution. The full-width-at-half-maximum for the section sensitivity profile was 0.33 mm for the smallest slice thickness (0.2 mm) using the UHR mode. Material decomposition in a multi-energy CT phantom showed accurate material classification, with a root-mean-squared-error of 0.3 mg cc −1 for iodine concentrations (2–15 mg cc −1 ) and 14.2 mg cc −1 for hydroxyapatite concentrations (200 and 400 mg cc −1 ). The average percent error for CT numbers corresponding to the iodine concentrations in VMI (40–70 keV) was 2.75%. Patient PCD-CT images demonstrated better delineation of anatomy for chest and temporal bone exams performed with the UHR mode, which allowed the use of very sharp kernels not possible with EID-CT. VMI and virtual non-contrast images generated from a patient head CT angiography exam using the standard acquisition mode demonstrated the multi-energy capability of the PCD-CT system.